In the case of a patient with AML who experienced extramedullary multifocal recurrence after SCT, neither local irradiation nor systemic treatment with the novel CD33-targeted antibody–drug conjugate had an effect on CR, which persisted for a long time after administration of VEN [17]; these findings are similar to those of some patients in our study. Here, CD33 is linked to acute myeloid leukemia.